A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Abstract Background The purpose of this study was to evaluate both the biodistribution and safety of 64Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel 64Cu-labeled positron emission tomography (PET) tracer for human epidermal growth factor receptor 2 (HER2) in patients wi...

Full description

Bibliographic Details
Main Authors: Inki Lee, Ilhan Lim, Byung Hyun Byun, Byung Il Kim, Chang Woon Choi, Sang-Keun Woo, Kwang Il Kim, Kyo Chul Lee, Joo Hyun Kang, Min-Ki Seong, Hyun-Ah Kim, Woo Chul Noh, Sang Moo Lim
Format: Article
Language:English
Published: SpringerOpen 2021-01-01
Series:EJNMMI Research
Subjects:
HER-2
64Cu-NOTA-Trastuzumab
Breast cancer
Positron emission tomography
Computed tomography
Online Access:https://doi.org/10.1186/s13550-021-00746-1

Internet

https://doi.org/10.1186/s13550-021-00746-1

Similar Items